日报更新时间：
周报更新时间：06-25 22:35
今开价：96.92
最高价：98.98
成交量：448028.0
昨收价：96.93
最低价：96.005
最新价：98.46
中文名称：神经分泌生物科学
英文名称：Neurocrine Biosciences
行业：医疗
简介：Neurocrine Biosciences, Inc.通过该公司的新研发平台为有大量医疗需求的疾病，发现和开发创新的和改变生活的药品，侧重于神经和内分泌的基础疾病和失调
电话：1-858-6177600
神经分泌生物科学公司是一家神经科学公司，着重于开发新型治疗神经与内分泌相关的疾病的药物，例如失眠、忧虑、消沉、多发性硬化症、糖尿病和内分泌相关的疾病。Neurocrine Biosciences公司临床开发阶段产品包括： elagolix——处于治疗子宫内膜异位症的III期临床试验阶段，处于治疗子宫肌瘤的IIb期临床试验阶段； 促肾上腺皮质激素释放因子受体1拮抗剂（Corticotropin-Releasing Factor Receptor1 Antagonist），目前处于治疗先天性肾上腺增生和压力有关的疾病的I/II期临床试验阶段； 囊泡单胺转运2抑制剂（VMAT2，Vesicular Monoamine Transporter 2 Inhibitor）——处于治疗运动障碍的III期临床试验阶段；同时处于治疗抽动秽语综合征的I期临床试验阶段。Neurocrine Biosciences公司研发阶段产品包括： VMAT2，用于治疗运动障碍、躁狂抑郁症和精神分裂症； 促性腺激素释放激素（GnRH）拮抗剂，对男性和女性的健康以及肿瘤学领域； 抗癫痫药物，用于治疗癫痫、原发性震颤、疼痛等； G蛋白偶联受体。此外，Neurocrine Biosciences公司还开发药物产品，用于治疗迟发性运动障碍，以及其它神经和内分泌有关的疾病和病症。Neurocrine Biosciences目前还与艾伯维公司（AbbVie Inc.）合作开发elagolix 和 GnRH产品，与Dainippon Sumitomo Pharma Co. Ltd.在日本合作开发indiplon（美国与辉瑞公司合作）。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-07-14 | Benevich (Eric S.) | Officer | Sell | 5835 | 87.44 |
| 2019-07-14 | Bozigian (Haig P) | Officer | Buy | 30680 | 32.99 |
| 2019-07-14 | Bozigian (Haig P) | Officer | Sell | 30680 | 87.50 |
| 2019-07-10 | Bozigian (Haig P) | Officer | Sell | 100 | 87.59 |
| 2019-07-10 | Bozigian (Haig P) | Officer | Buy | 100 | 32.99 |
| 2019-07-09 | Bozigian (Haig P) | Officer | Buy | 7120 | 32.99 |
| 2019-07-09 | Bozigian (Haig P) | Officer | Sell | 7120 | 87.63 |
| 2019-06-17 | Bozigian (Haig P) | Officer | Buy | 2100 | 32.99 |
| 2019-06-17 | Bozigian (Haig P) | Officer | Sell | 2100 | 87.82 |
| 2019-06-12 | Bozigian (Haig P) | Officer | Buy | 1432 | 32.99 |
| 2019-06-12 | Bozigian (Haig P) | Officer | Buy | 15836 | 19.59 |
| 2019-06-12 | Bozigian (Haig P) | Officer | Sell | 15836 | 82.56 |
| 2019-06-12 | Bozigian (Haig P) | Officer | Sell | 1432 | 83.29 |
| 2019-06-02 | Bozigian (Haig P) | Officer | Buy | 3435 | 19.59 |
| 2019-06-02 | Bozigian (Haig P) | Officer | Sell | 3435 | 85.51 |
| 2019-05-30 | Bozigian (Haig P) | Officer | Sell | 19297 | 85.02 |
| 2019-05-30 | Bozigian (Haig P) | Officer | Buy | 19297 | 19.59 |
| 2019-05-23 | Bozigian (Haig P) | Officer | Sell | 17486 | 80.03 |
| 2019-05-23 | Bozigian (Haig P) | Officer | Buy | 17486 | 19.59 |
| 2019-05-21 | Bozigian (Haig P) | Officer | Sell | 1300 | 80.03 |
| 2019-05-21 | Bozigian (Haig P) | Officer | Buy | 1300 | 19.59 |
| 2019-05-15 | Bozigian (Haig P) | Officer | Sell | 22439 | 80.13 |
| 2019-05-15 | Bozigian (Haig P) | Officer | Buy | 22439 | 35.99 |
| 2019-05-15 | Bozigian (Haig P) | Officer | Sell | 34376 | 80.13 |
| 2019-05-15 | Bozigian (Haig P) | Officer | Sell | 731 | 80.13 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Orbimed Advisors, LLC | 1833200 | 2.01% | 1339000 | 270.94% | 2019-03-31 |
| Fidelity Management & Research Company | 4487154 | 4.90% | -714802 | -13.74% | 2019-07-31 |
| BlackRock Inc | 5495336 | 6.02% | 516419 | 10.37% | 2019-03-31 |
| Capital Research and Management Company | 5653200 | 6.17% | 1204600 | 27.08% | 2019-07-31 |
| Vanguard Group Inc | 8155857 | 8.93% | 76039 | 0.94% | 2019-03-31 |
| Janus Capital Management LLC | 8361282 | 9.13% | 493615 | 6.27% | 2019-07-31 |
| HHG PLC | 8811961 | 9.65% | 4547 | 0.05% | 2019-03-31 |
| Fidelity Management and Research Company | 9053989 | 9.92% | -2516225 | -21.75% | 2019-03-31 |
| FMR Inc | 10437053 | 11.43% | -2579538 | -19.82% | 2019-03-31 |
| Capital Research & Mgmt Co - Division 3 | 4426600 | 4.85% | 901600 | 25.58% | 2019-03-31 |
| Fidelity SelectCo, LLC | 3853799 | 4.21% | 38580 | 1.01% | 2019-07-31 |
| Perceptive Advisors LLC | 3758662 | 4.12% | -849892 | -18.44% | 2019-03-31 |
| State Street Corporation | 2018154 | 2.21% | 177309 | 9.63% | 2019-03-31 |
| Franklin Advisers, Inc. | 2039138 | 2.23% | 14200 | 0.70% | 2019-03-31 |
| Franklin Resources Inc | 2039138 | 2.23% | 14200 | 0.70% | 2019-03-31 |
| BlackRock Fund Advisors | 2047586 | 2.24% | 9125 | 0.45% | 2019-07-31 |
| Vanguard Investments Australia Ltd | 2532855 | 2.77% | 332 | 0.01% | 2019-07-31 |
| BB Biotech AG | 3366786 | 3.69% | 23696 | 0.71% | 2019-03-31 |
| T. Rowe Price Associates, Inc. | 3476150 | 3.81% | -533213 | -13.30% | 2019-03-31 |
| Bellevue Asset Management AG | 3507644 | 3.83% | 106708 | 3.14% | 2019-07-31 |
| Amvescap Plc. | 2128862 | 2.33% | -4180 | -0.20% | 2018-12-31 |
| Deutsche Asset Management Investment GmbH | 3158974 | 3.46% | 2397167 | 314.67% | 2019-05-31 |
| Artisan Partners Limited Partnership | 1672187 | 1.84% | -165077 | -8.98% | 2018-12-31 |
| Fidelity Institutional Asset Management | 1435253 | 1.58% | -31949 | -2.18% | 2018-09-30 |
| Invesco Advisers, Inc | 1908941 | 2.11% | -285534 | -13.01% | 2018-06-30 |
| BlackRock Institutional Trust Company NA | 2395891 | 2.64% | -47509 | -1.94% | 2018-06-30 |
| Wellington Management Company LLP | 2405500 | 2.65% | 33827 | 1.43% | 2018-06-30 |
| Franklin Advisers Inc | 1825386 | 2.02% | -531200 | -22.54% | 2018-06-30 |
| State Street Corp | 1774067 | 1.96% | -149001 | -7.75% | 2018-06-30 |
| TimesSquare Capital Management, LLC | 1481612 | 1.64% | -318450 | -17.69% | 2018-06-30 |
| AllianceBernstein LP | 1164900 | 1.29% | -82597 | -6.62% | 2018-06-30 |
| Wells Capital Management Inc. | 1009144 | 1.12% | 103368 | 11.41% | 2018-06-30 |
| First Trust Advisors L.P. | 979671 | 1.08% | 52200 | 5.63% | 2018-06-30 |
| Baker Bros Advisors LP | 944624 | 1.04% | -- | -- | 2018-06-30 |
| Point72 Asset Management, L.P. | 895900 | 0.99% | 820900 | 1094.53% | 2018-06-30 |
| Pictet Asset Management SA | 939871 | 1.05% | -180790 | -16.13% | 2018-03-31 |
| Goldman, Sachs & Co. | 921517 | 1.03% | -325185 | -26.08% | 2018-03-31 |
| Healthcor Management LP | 1525000 | 1.72% | -562110 | -26.93% | 2017-12-31 |
| Goldman Sachs Asset Management LP | 1005549 | 1.14% | -118535 | -10.55% | 2017-09-30 |
| Arrowpoint Asset Management, LLC | 887946 | 1.00% | -7633 | -0.85% | 2017-09-30 |
| Capital World Investors | 1481000 | 1.70% | -- | -- | 2016-09-30 |
| Westfield Capital Management Company, LP | 1255995 | 1.45% | -19580 | -1.53% | 2016-09-30 |
| Senator Investment Group LP | 1150000 | 1.32% | 300000 | 35.29% | 2016-09-30 |
| Citadel Advisors Llc | 1037519 | 1.19% | 103974 | 11.14% | 2016-09-30 |
| OppenheimerFunds Inc | 1002548 | 1.15% | 170680 | 20.52% | 2016-09-30 |
| BlackRock Advisors LLC | 943190 | 1.09% | -17066 | -1.78% | 2016-09-30 |
| Eagle Asset Management, Inc. | 914500 | 1.05% | -27153 | -2.88% | 2016-09-30 |
| BlackRock, Inc. | 6347260 | 3.00% | 259983770 | 0.10% | 1999-11-30 |
| FMR LLC | 11400773 | 3.00% | 466975662 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Fidelity Advisor | 726352 | 0.79% | 55200 | 8.22% | 2019-06-30 |
| American Funds Growth Fund of Amer | 3890500 | 4.25% | 1002500 | 34.71% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 2512304 | 2.74% | 451 | 0.02% | 2019-06-30 |
| Vanguard Small Cap Index | 2333511 | 2.55% | -36341 | -1.53% | 2019-06-30 |
| Janus Henderson Enterprise Fund | 1826798 | 1.99% | -- | -- | 2019-06-30 |
| Janus Mid Cap Growth Tr | 1826798 | 1.99% | -- | -- | 2019-06-30 |
| Vanguard Small Cap Growth Index Fund | 1337641 | 1.46% | -6974 | -0.52% | 2019-06-30 |
| T. Rowe Price Health Sciences Fund | 1332018 | 1.45% | -71800 | -5.11% | 2019-06-30 |
| Vanguard Extended Market Index Fund | 1256107 | 1.37% | -2430 | -0.19% | 2019-06-30 |
| Janus Henderson Research Fund | 1185766 | 1.29% | -92602 | -7.24% | 2019-06-30 |
| First Trust NYSE Arca Biotech Fund | 1106202 | 1.21% | -2666 | -0.24% | 2019-07-31 |
| Janus Henderson Triton Fund | 1032834 | 1.13% | -- | -- | 2019-06-30 |
| Janus Henderson Global Life Sciences Fd | 1018139 | 1.11% | -14824 | -1.44% | 2019-06-30 |
| American Funds Fundamental Invs | 1009400 | 1.10% | 93200 | 10.17% | 2019-06-30 |
| T. Rowe Price New Horizons Fund | 928685 | 1.01% | -3000 | -0.32% | 2019-06-30 |
| iShares Nasdaq Biotechnology ETF | 901144 | 0.98% | 9383 | 1.05% | 2019-07-30 |
| Fidelity | 743400 | 0.81% | -- | -- | 2019-06-30 |
| SPDR | 700767 | 0.77% | -5560 | -0.79% | 2019-06-28 |
| DWS Verm | 1680000 | 1.84% | 1260000 | 300.00% | 2019-04-30 |
| Vanguard Small Cap Index Fund | 2372517 | 2.60% | 15166 | 0.64% | 2019-04-30 |
| VA CollegeAmerica The Gr Fd of Amer | 2738000 | 3.01% | 2738000 | -- | 2018-12-31 |
| Artisan Mid Cap Fund | 674514 | 0.74% | -- | -- | 2018-10-31 |
| Franklin Biotechnology Discovery Fund | 649305 | 0.72% | 151300 | 30.38% | 2018-11-30 |
| iShares Nasdaq Biotechnology | 1019947 | 1.12% | -1941 | -0.19% | 2018-09-12 |
| Artisan Mid Cap Investor | 732194 | 0.81% | -67299 | -8.42% | 2018-06-30 |
| Janus Global Life Sciences D | 787513 | 0.87% | -68721 | -8.03% | 2018-06-30 |
| T. Rowe Price Health Sciences | 2350166 | 2.60% | -35742 | -1.50% | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 2255500 | 2.49% | 2346 | 0.10% | 2018-07-31 |
| Janus Enterprise D | 1825633 | 2.02% | -- | -- | 2018-06-30 |
| T. Rowe Price New Horizons | 1788746 | 1.98% | -157063 | -8.07% | 2018-06-30 |
| Vanguard Small Cap Growth Index Inv | 1291418 | 1.43% | 18334 | 1.44% | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 1191667 | 1.32% | -- | -- | 2018-07-31 |
| Hartford MidCap A | 1187436 | 1.31% | -133846 | -10.13% | 2018-07-31 |
| Janus Research D | 1140748 | 1.26% | -- | -- | 2018-06-30 |
| Janus Triton D | 889607 | 0.98% | -- | -- | 2018-06-30 |
| First Trust NYSE Arca Biotech ETF | 718040 | 0.78% | -- | -- | 2018-09-13 |
| VA CollegeAmerica Smcap World 529E | 658000 | 0.73% | -30000 | -4.36% | 2018-06-30 |
| Delaware Smid Cap Growth A | 597225 | 0.66% | 26125 | 4.57% | 2018-05-31 |
| Invesco Mid Cap Growth A | 645904 | 0.72% | -132041 | -16.97% | 2018-03-31 |
| Invesco Mid Cap Growth | 645904 | 0.72% | 635644 | 6195.36% | 2018-03-31 |
| Franklin Biotechnology Discovery A | 740100 | 0.83% | -158300 | -17.62% | 2017-12-31 |
| T. Rowe Price Mid-Cap Growth | 850000 | 0.98% | 850000 | -- | 2016-09-30 |
| Fidelity® Contrafund® Fund | 2136614 | 2.50% | 325855 | 18.00% | 2015-09-30 |
| iShares Russell 2000 (AU) | 1352605 | 1.70% | -1704 | -0.10% | 2015-11-19 |
| Fidelity® Select Health Care Portfolio | 1100000 | 1.30% | -- | -- | 2015-09-30 |
| Fidelity® OTC Portfolio | 984200 | 1.10% | 345747 | 54.10% | 2015-09-30 |
| VA CollegeAmerica Small Cap World | 927500 | 1.10% | -170200 | -15.50% | 2015-09-30 |
| Janus Global Life Sciences Fund | 898044 | 1.10% | -121463 | -11.90% | 2015-09-30 |
| Fidelity® Select Biotechnology Portfolio | 3582851 | 4.20% | -- | -- | 2015-09-30 |
| Stephen A. Sherwin | Stephen A. Sherwin founded Abgenix, Inc. and Ceregene, Inc. Dr. Sherwin is Member of American Society of Clinical Oncology, Member of American Association for Cancer Research, Venture Partner at Third Rock Ventures LLC, Professor at the University of California and Clinical Professor at The University of California, San Francisco and on the board of 6 other companies. He previously was Chairman & Chief Executive Officer of Cell Genesys, Inc., Chairman at Abgenix, Inc., Chairman of Ceregene, Inc., Vice President-Clinical Research at Genentech, Inc., Director at Biogen Idec New Ventures, Inc., Chairman-Emeritus at Biotechnology Innovation Organization and Principal at National Cancer Institute. He received an undergraduate degree from Yale University and a doctorate from Harvard Medical School. |
|---|---|
| George J. Morrow | George J. Morrow is on the board of Vical, Inc., Neurocrine Biosciences, Inc. and Align Technology, Inc. Mr. Morrow previously occupied the position of Executive VP-Global Commercial Operations at Amgen, Inc., Vice President-Marketing of Merck & Co., Inc. and President, Chief Executive Officer & Director at Glaxo Wellcome, Inc. He received a graduate degree from Bryn Mawr College, an MBA from The Fuqua School of Business, an undergraduate degree from Southampton City College, an MBA from Duke University and an undergraduate degree from Long Island University. |
| Kevin Charles Gorman | Kevin Charles Gorman founded Neurocrine Biosciences, Inc. Currently, Dr. Gorman is Chief Executive Officer & Director at this company. He is also on the board of Xencor, Inc. In the past Dr. Gorman held the position of Principal at Avalon Medical Partners LP. Dr. Gorman received a doctorate and an MBA from the University of California, Los Angeles. |
| Richard F. Pops | Mr. Richard F. Pops is Independent Director at Neurocrine Biosciences, Inc., Chairman, President & Chief Executive Officer at Alkermes, Inc., Chairman & Chief Executive Officer at Alkermes Plc, a Member at Harvard Medical School, and Strategic Advisor at Longwood Fund Management LLC. He is on the Board of Directors at Reliant Pharmaceuticals LLC, Neurocrine Biosciences, Inc., Acceleron Pharma, Inc., Expressive Constructs, Inc., Biotechnology Industry Organization, New England Healthcare Institute, Pharmaceutical Research & Manufacturers of America, and Epizyme, Inc. Mr. Pops also served on the board at Sirtris Pharmaceuticals, Inc. and CombinatoRx, Inc. Mr. Pops received his undergraduate degree from Stanford University. |
| Timothy P. Coughlin | Presently, Timothy P. Coughlin is Vice President of Neurocrine Biosciences, Inc. Mr. Coughlin is also on the board of aTyr Pharma, Inc., Peloton Therapeutics, Inc., Fate Therapeutics, Inc. and Retrophin, Inc. In the past Mr. Coughlin held the position of Vice President-Financial Services at California Healthcare Institute and Senior Manager-Health Sciences Practice at Ernst & Young LLP. Mr. Coughlin received an undergraduate degree from Temple University (Pennsylvania) and a graduate degree from San Diego State University. |
| Darin M. Lippoldt | Currently, Darin M. Lippoldt is Secretary & Chief Legal Officer of Neurocrine Biosciences, Inc. He previously held the position of Associate General Counsel at Amylin Pharmaceuticals, Inc. and Secretary, Chief Compliance Officer & Executive VP at Volcano Corp. He received an undergraduate degree and a graduate degree from St. Mary's University. |
| William H. Rastetter | Founder of Receptos LLC and Apoptos, Inc., William H. Rastetter is a businessperson who has been at the head of 11 different companies and presently is Chairman at Fate Therapeutics, Inc., Chairman for Neurocrine Biosciences, Inc. and Advisor at IIF Management Co. LLC. Dr. Rastetter is also on the board of 5 other companies. In the past Dr. Rastetter occupied the position of Chairman of Celgene Corp. Executive Chairman for Receptos LLC and Chairman & Chief Executive Officer of Apoptos, Inc. (both are subsidiaries of Celgene Corp.), Executive Chairman for Biogen, Inc. and Chairman & Chief Executive Officer at IDEC Pharmaceuticals Corp. (a subsidiary of Biogen, Inc.), Chairman of Illumina, Inc., Partner at Venrock Associates, Chairman of Cerulean Pharma, Inc., Director-Corporate Ventures at Genentech, Inc., Associate Professor at Massachusetts Institute of Technology and Faculty Member at Harvard University. William H. Rastetter received a doctorate and a graduate degree from Harvard University and an undergraduate degree from Massachusetts Institute of Technology. |
| Richard F. Pops | Mr. Richard F. Pops is Independent Director at Neurocrine Biosciences, Inc., Chairman, President & Chief Executive Officer at Alkermes, Inc., Chairman & Chief Executive Officer at Alkermes Plc, a Member at Harvard Medical School, and Strategic Advisor at Longwood Fund Management LLC. He is on the Board of Directors at Reliant Pharmaceuticals LLC, Neurocrine Biosciences, Inc., Acceleron Pharma, Inc., Expressive Constructs, Inc., Biotechnology Industry Organization, New England Healthcare Institute, Pharmaceutical Research & Manufacturers of America, and Epizyme, Inc. Mr. Pops also served on the board at Sirtris Pharmaceuticals, Inc. and CombinatoRx, Inc. Mr. Pops received his undergraduate degree from Stanford University. |
| Richard F. Pops | Mr. Richard F. Pops is Independent Director at Neurocrine Biosciences, Inc., Chairman, President & Chief Executive Officer at Alkermes, Inc., Chairman & Chief Executive Officer at Alkermes Plc, a Member at Harvard Medical School, and Strategic Advisor at Longwood Fund Management LLC. He is on the Board of Directors at Reliant Pharmaceuticals LLC, Neurocrine Biosciences, Inc., Acceleron Pharma, Inc., Expressive Constructs, Inc., Biotechnology Industry Organization, New England Healthcare Institute, Pharmaceutical Research & Manufacturers of America, and Epizyme, Inc. Mr. Pops also served on the board at Sirtris Pharmaceuticals, Inc. and CombinatoRx, Inc. Mr. Pops received his undergraduate degree from Stanford University. |
| Gary A. Lyons | Founder of GL Biomed, Gary A. Lyons is a businessperson who has been at the head of 5 different companies and presently is Chairman for Retrophin, Inc., Chairman at Rigel Pharmaceuticals, Inc. and President of GL Biomed. Mr. Lyons is also on the board of Vical, Inc., Neurocrine Biosciences, Inc. (former President, Chief Executive Officer & Director) and Novus Therapeutics, Inc. In his past career Mr. Lyons was Executive Chairman of NeurogesX, Inc., Sales Director-American Critical Care at American Hospital Supply Corp. and Vice President-Business Development & Sales at Genentech, Inc. Mr. Lyons received an undergraduate degree from the University of New Hampshire and an MBA from Kellogg School of Management. |
| Julie Cooke | Currently, Julie Cooke is Chief Human Resources Officer at Neurocrine Biosciences, Inc. In her past career she occupied the position of Compensation Director at Pepsi-Cola North America, Director-Human Resources for Gateway Computers, Vice President-Human Resources for Life Technologies Corp., Vice President-Human Resources for SGX Pharmaceuticals, Inc. and Senior Vice President-Human Resources of Sanford Burnham Prebys Medical Discovery Institute. Ms. Cooke received an undergraduate degree from Colorado College. |
| Haig P. Bozigian | Haig P. Bozigian is Chief Development Officer for Neurocrine Biosciences, Inc. Dr. Bozigian previously was Associate Director-Pharmacokinetics at Sphinx Pharmaceuticals Corp and Director-Pharmaceutical Development at ProCyte Corp. Haig P. Bozigian received an undergraduate degree from the University of Massachusetts, a doctorate from the University of Arizona and a graduate degree from the University of Nebraska Medical Center. |
| Dimitri E. Grigoriadis | Presently, Dimitri E. Grigoriadis holds the position of Chief Research Officer at Neurocrine Biosciences, Inc. Dr. Grigoriadis is also Member of International Society of Psychoneuroendocrinology. Dr. Grigoriadis previously occupied the position of Senior Scientist-Neuroscience Group at DuPont Pharmaceuticals Co. Dr. Grigoriadis received an undergraduate degree from the University of Guelph and a doctorate and a graduate degree from the University of Toronto. |
| Bill Wilson | Presently, Bill Wilson holds the position of Vice President-Information Technology & Operations at Neurocrine Biosciences, Inc. Mr. Wilson is also Founding Member at CIO Executive Council. |
| Eric S. Benevich | Eric S. Benevich is Chief Commercial Officer at Neurocrine Biosciences, Inc. Mr. Benevich previously occupied the position of Senior Director-Marketing at Peninsula Pharmaceuticals, Inc. and Vice President-Communications & Marketing at Avanir Pharmaceuticals, Inc. Eric S. Benevich received an undergraduate degree from Washington State University. |
| Malcolm Lloyd-Smith | Presently, Malcolm Lloyd-Smith is Chief Regulatory Officer at Neurocrine Biosciences, Inc. He previously occupied the position of Vice President-Worldwide Regulatory Affairs at DuPont Pharmaceuticals Co., Director-International Regulatory Affairs at DuPont Merck Pharmaceutical Co., Senior VP-Regulatory Affairs, Quality & Clinical at Mallinckrodt Hospital Products, Inc., Manager-Regulatory Affairs & Quality Assurance at DuPont de Nemours International SARL and Vice President & Head-Global Regulatory Affairs at Elan Pharmaceuticals, Inc. Malcolm Lloyd-Smith received an undergraduate degree from the University of Leeds and a graduate degree from the University of Hertfordshire. |
| Bill Wilson | Presently, Bill Wilson holds the position of Vice President-Information Technology & Operations at Neurocrine Biosciences, Inc. Mr. Wilson is also Founding Member at CIO Executive Council. |
| Gary A. Lyons | Gary A. Lyons is a businessperson who founded GL Biomed and who has been at the helm of 5 different companies. Currently, Mr. Lyons occupies the position of Chairman for Retrophin, Inc., Chairman of Rigel Pharmaceuticals, Inc. and President at GL Biomed. He is also on the board of Vical, Inc., Neurocrine Biosciences, Inc. (former Chief Executive Officer), Cytori Therapeutics, Inc. and Novus Therapeutics, Inc. In the past he was Executive Chairman for NeurogesX, Inc., Sales Director-American Critical Care at American Hospital Supply Corp. and Vice President-Business Development & Sales at Genentech, Inc. Gary A. Lyons received an undergraduate degree from the University of New Hampshire and an MBA from Kellogg School of Management. |
| Alfred W. Sandrock | Presently, Alfred W. Sandrock occupies the position of Chief Medical Officer & Executive Vice President at Biogen, Inc. and Chief Medical Officer of Biogen Idec, Inc. (North Carolina) (a subsidiary of Biogen, Inc.). Dr. Sandrock is also on the board of Neurocrine Biosciences, Inc. and Disarm Therapeutics, Inc. and Professor at Harvard Medical School and Member of American Academy of Neurology. Dr. Sandrock received a doctorate from Harvard Medical School, a doctorate from Harvard University and an undergraduate degree from Stanford University. |
| George J. Morrow | George J. Morrow is on the board of Vical, Inc., Neurocrine Biosciences, Inc. and Align Technology, Inc. Mr. Morrow previously occupied the position of Executive VP-Global Commercial Operations at Amgen, Inc., Vice President-Marketing of Merck & Co., Inc. and President, Chief Executive Officer & Director at Glaxo Wellcome, Inc. He received a graduate degree from Bryn Mawr College, an MBA from The Fuqua School of Business, an undergraduate degree from Southampton City College, an MBA from Duke University and an undergraduate degree from Long Island University. |
| Kyle Gano | Kyle Gano is Chief Business Development Officer at Neurocrine Biosciences, Inc. He received an undergraduate degree from the University of Oregon, an undergraduate degree from the University of Washington and a doctorate and an MBA from the University of California, Los Angeles. |
| Matthew C. Abernethy | Presently, Matthew C. Abernethy holds the position of Chief Financial Officer at Neurocrine Biosciences, Inc., Vice President-Finance for Biomet Orthopedics LLC and Treasurer of Biomet, Inc. Mr. Abernethy is also on the board of BIOCOM. He previously held the position of Vice President, Investor Relations & Treasurer at Zimmer Biomet Holdings, Inc. and Treasurer for Zimmer US, Inc. (a subsidiary of Zimmer Biomet Holdings, Inc.). He received an undergraduate degree from Grace College & Seminary and an MBA from The University of Chicago. |
| Eiry W. Roberts | Eiry W. Roberts occupies the position of Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts previously held the position of Vice President-Autoimmune Product Development at Eli Lilly & Co. |
| Navjot Rai | Currently, Navjot Rai occupies the position of Investor Relations Contact at Neurocrine Biosciences, Inc. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论